Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | IDH1 | O75874 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571566 | 0.86 | SMN1; SMN2 (0.57) | ALDH1A1SMN1; SMN2IDH1L3MBTL1MAPT | |
| SCHEMBL95317 | 0.86 | SMN1; SMN2 (0.60) | ALDH1A1GAASMN1; SMN2IDH1L3MBTL1 | |
| SCHEMBL7580547 | 0.86 | IDH1 (0.71) | SMN1; SMN2IDH1L3MBTL1 | |
| SCHEMBL7572373 | 0.86 | L3MBTL1 (0.67) | ALDH1A1SMN1; SMN2IDH1L3MBTL1MAPT | |
| SCHEMBL7571531 | 0.84 | SMN1; SMN2 (0.67) | ALDH1A1GAATSHRSMN1; SMN2IDH1 | |
| SCHEMBL18995908 | 0.81 | GAA (0.75) | ALDH1A1GAATSHRSMN1; SMN2GFER | |
| SCHEMBL259390 | 0.80 | MEN1 (0.66) | ALDH1A1SMN1; SMN2IDH1L3MBTL1MAPT | |
| SCHEMBL7571583 | 0.79 | MEN1 (0.63) | ALDH1A1GAASMN1; SMN2IDH1L3MBTL1 | |
| SCHEMBL11442412 | 0.78 | CA2 (0.71) | ALDH1A1GAASMN1; SMN2GFERMAPT | |
| SCHEMBL29451393 | 0.78 | ALDH1A1 (0.62) | ALDH1A1TSHRSMN1; SMN2L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202339-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202339-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20150299115-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2906212-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014062511-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202339-B2 | Therapeutic compounds and compositions | IDH3A, IDH1, IDH2 | ALDH1A1 84/4885GAA 2065/4885TSHR 4111/4885 |
| US-20150299115-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | IDH3A, IDH1, IDH2 | ALDH1A1 84/4885GAA 2065/4885TSHR 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.